Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Chronic myeloid leukemia


Other Names for this Disease

  • Chronic granulocytic leukemia
  • Chronic myelogenous leukemia
  • CML
  • Leukemia, chronic myeloid
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Chronic myeloid leukemia. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
  • The¬†Myeloproliferative Disorders¬†Research Consortium (MPD-RC) is an international, multi-institutional non-profit consortium funded by the National Cancer Institute (NCI) at the National Institutes of Health and set up to coordinate, facilitate, and perform basic and clinic research investigating the genetics of MPDs with the goal of developing therapy. To learn more, click on the link.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Bosutinib
Trade Name
(Manufacturer Name)
Bosulif
(Wyeth Pharmaceuticals, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of adult patients with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy
More Information about this product Drug Information Portal

Generic Name Imatinib mesylate
Trade Name
(Manufacturer Name)
Gleevec®
(Novartis Pharmaceuticals Corp.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of chronic myelogenous leukemia
More Information about this product Drug Information Portal

Generic Name Ponatinib
Trade Name
(Manufacturer Name)
Iclusig
(ARIAD Pharmaceuticals Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
More Information about this product Drug Information Portal

Generic Name Interferon alfa-2a (recombinant)
Trade Name
(Manufacturer Name)
Roferon®-A
(Hoffmann-La Roche, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of chronic myelogenous leukemia.
More Information about this product Drug Information Portal

Generic Name Dasatinib
Trade Name
(Manufacturer Name)
Sprycel®
(Bristol-Myers Squibb Company)
Indication
The FDA has approved this product to be used in this manner.
Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy
More Information about this product Drug Information Portal

Generic Name Omacetaxine mepesuccinate
Trade Name
(Manufacturer Name)
Synribo
(Teva Pharmaceuticals)
Indication
The FDA has approved this product to be used in this manner.
Treatment of chronic myelogenous leukemia
More Information about this product Drug Information Portal

Generic Name Nilotinib
Trade Name
(Manufacturer Name)
Tasigna®
(Novartis Pharmaceutical Corporation)
Indication
The FDA has approved this product to be used in this manner.
For the use for chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior therapy that included Gleevec(imatinib)
More Information about this product Drug Information Portal
Medline Plus Health Information

Other Names for this Disease
  • Chronic granulocytic leukemia
  • Chronic myelogenous leukemia
  • CML
  • Leukemia, chronic myeloid
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.